The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The primary goal of the collaboration is joint research into trending and next-generation molecules
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Subscribe To Our Newsletter & Stay Updated